{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:58:10Z","timestamp":1789387090555,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.ejphar.2014.02.027","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T09:02:56Z","timestamp":1393923776000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior"],"prefix":"10.1016","volume":"730","author":[{"given":"Robert A.","family":"Hodgson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborra","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry X.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Guzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina J.","family":"Bleickardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack D.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Stamford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey B.","family":"Varty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2014.02.027_bib1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/sj.mp.4001464","article-title":"Blockade of CRF(1) or V(1b) receptors reversed stress-induced suppression of neurogenesis in a mouse model of depression","volume":"9","author":"Alonso","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.ejphar.2014.02.027_bib2","first-page":"126","article-title":"Effect of vasopressin V1b receptor antagonist, SSR149415, on anxiety-like behavior and Lewis lung carcinoma metastasis in mice","volume":"3","author":"Amikishieva","year":"2011","journal-title":"Exp. Oncol."},{"key":"10.1016\/j.ejphar.2014.02.027_bib3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0031-9384(98)00119-X","article-title":"Vasopressin administration modulates anxiety-related behavior in rats","volume":"64","author":"Appenrodt","year":"1998","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ejphar.2014.02.027_bib4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0031-9384(99)00237-1","article-title":"Central vasopressin administration failed to influence anxiety behavior after pinealectomy in rats","volume":"68","author":"Appenrodt","year":"2000","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ejphar.2014.02.027_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00213-008-1354-x","article-title":"Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior","volume":"202","author":"Bleickardt","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2014.02.027_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00210-008-0336-1","article-title":"SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model","volume":"379","author":"Breuer","year":"2009","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.02.027_bib7","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.02.027_bib8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0079-6123(08)00440-8","article-title":"Characterization of a novel and selective V1B receptor antagonist","volume":"170","author":"Craighead","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ejphar.2014.02.027_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/11539050-000000000-00000","article-title":"Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence","volume":"34","author":"Dassanayake","year":"2012","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2014.02.027_bib10","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1073\/pnas.092012099","article-title":"Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders","volume":"30","author":"Griebel","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2014.02.027_bib11","series-title":"Characterization of a Novel Nonselective V1a\/b Antagonist (SCH 756491) in Animal Models of Anxiety-like Behavior, 828.6. Neuroscience Meeting Planner","author":"Hodgson","year":"2006"},{"key":"10.1016\/j.ejphar.2014.02.027_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pbb.2007.09.005","article-title":"Duration of ultrasonic vocalizations in the isolated rat pup as a behavioral measure: sensitivity to anxiolytic and antidepressant drugs","volume":"88","author":"Hodgson","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.ejphar.2014.02.027_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.pbb.2006.12.021","article-title":"Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression","volume":"86","author":"Hodgson","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2014.02.027_bib33","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.pbb.2005.11.005","article-title":"Separation-induced ultrasonic vocalization in rat pups: further pharmacological characterization","volume":"82","author":"Iijima","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.ejphar.2014.02.027_bib13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.pnpbp.2006.12.008","article-title":"An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model","volume":"31","author":"Iijima","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2014.02.027_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/187152707780619344","article-title":"The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders","volume":"6","author":"Kehne","year":"2007","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.ejphar.2014.02.027_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2265.1978.tb02156.x","article-title":"The effect of pain on plasma arginine vasopressin concentrations in man","volume":"8","author":"Kendler","year":"1978","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ejphar.2014.02.027_bib16","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.2174\/138161212803530871","article-title":"Neuropeptides as therapeutic targets in anxiety disorders","volume":"18","author":"Lin","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2014.02.027_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2011.04.034","article-title":"The anxiolytic-like profile of the nociceptin NOP receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): Comparison of efficacy and side-effects across rodent species","volume":"661","author":"Lu","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.02.027_bib18","first-page":"287","article-title":"Effects of 28-day isolation (ESA-ISEMSI\u05f390) on blood pressure and blood volume regulating hormones","volume":"64","author":"Maillet","year":"1993","journal-title":"Aviat Space Environ. Med."},{"key":"10.1016\/j.ejphar.2014.02.027_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-4684-5799-5_6","article-title":"Neuroendocrine responses to emotional stress: possible interactions between circulating factors and anterior pituitary hormone release","volume":"274","author":"Meyerhoff","year":"1990","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejphar.2014.02.027_bib20","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.bmcl.2010.12.081","article-title":"Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists","volume":"21","author":"Napier","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2014.02.027_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pbb.2005.07.021","article-title":"Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat","volume":"83","author":"Overstreet","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2014.02.027_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archpsyc.1996.01830020055007","article-title":"Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression","volume":"53","author":"Purba","year":"1996","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ejphar.2014.02.027_bib23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/sj.npp.1301403","article-title":"Are GABAA receptors containing \u03b15 subunits contributing to the sedative properties of benzodiazepine site agonists?","volume":"33","author":"Savi\u0107","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2014.02.027_bib24","first-page":"277","article-title":"pAx and competitive drug antagonism","volume":"4","author":"Schild","year":"1949","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.02.027_bib25","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1016\/j.bmcl.2009.09.050","article-title":"Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists","volume":"19","author":"Scott","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2014.02.027_bib26","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1124\/jpet.300.3.1122","volume":"300","author":"Serradeil-Le Gal","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2014.02.027_bib27","first-page":"53","article-title":"An overview of SSR149415, a selective nonpeptide vasopressin V1b receptor antagonist for the treatment of stress related disorders","volume":"11","author":"Serradeil-Le Gal","year":"2005","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ejphar.2014.02.027_bib28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1172\/JCI200419656","article-title":"The vasopressin V1b receptor critically regulates hypothalamic- pituitary-adrenal axis activity under both stress and resting conditions","volume":"113","author":"Tanoue","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2014.02.027_bib29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0893-133X(97)00054-7","article-title":"Plasma levels of arginine vasopressin elevated in patients with major depression","volume":"17","author":"van Londen","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2014.02.027_bib30","first-page":"207","article-title":"The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: A comparison of efficacy and side-effect profiles","author":"Varty","year":"2005","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejphar.2014.02.027_bib31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00213-005-0041-4","article-title":"Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species","author":"Varty","year":"2005","journal-title":"Psychopharmacology"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914001563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914001563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T03:20:54Z","timestamp":1538796054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299914001563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":33,"alternative-id":["S0014299914001563"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.02.027","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}